Here's Why Deciphera Pharmaceuticals Tumbled Today
The company announced a public stock offering as it prepares for a potential regulatory approval in 2020.
Twist Bioscience Pursues Growth at All Costs. How Long Will Investors Tolerate It?
The biggest source of uncertainty has been removed, allowing Wall Street to focus on the company's growth and financials. But investors should be careful what they wish for.
2 Stocks to Buy and Hold for Decades
These two stocks are supported by solid long-term opportunities, but they couldn't be more different.
2 Stocks to Hold for the Next 20 Years
The world's leading lithium producer and one of America's greenest electric utilities are great investments for investors with a long-term mindset.
Here's Why Adverum Biotechnologies Is Soaring Today
Interim results from an early-stage study of its wet age-related macular degeneration treatment look promising.
Stocks to Watch in February
These three stocks have major events coming up this month -- and it's not just the release of earnings that investors will be watching.
2 Recession-Ready Stocks to Buy Right Now
Recession or not, these two utilities will keep delivering the electricity, natural gas, and water that make modern life possible.
Here's Why Sorrento Therapeutics Shares Jumped 13.3% in January
The pharmaceutical stock soared after being approached for an acquisition, but has tanked in the weeks since management announced it has declined the offer.
Here's Why International Paper Stock Fell 11.6% in January
Investors initially were displeased with full-year 2019 operating results, but shares have bounced back in February.
Here's Why Incyte Stock Tumbled 16.3% in January
A failed study disappointed investors, but the company's pipeline should withstand the blow.
Here's Why Enphase Energy Stock Jumped 20.6% in January
Investors continue to gobble up shares of the fast-growing company.
Here's Why Collegium Pharmaceutical Rose as Much as 20.7% Today
The speciality pharmaceutical company purchased the full rights to an important drug product.
Here's Why Zogenix Took a Tumble Today
Despite reports of positive late-stage results for an important drug candidate, Wall Street was hoping for more.
Here's Why Arrowhead Pharmaceuticals Fell 33.9% in January
Investors began to question the excessive market valuation for the early-stage biopharma, but the company still has plenty of potential.
Here's Why LNG Shipping Stocks Fell as Much as 52.1% Today
GasLog offered mixed comments on the state of the market, announced major impairment charges, and slashed its distribution.
Here's Why Cardinal Health Rose as Much as 13.7% Today
The healthcare company reported solid quarterly earnings and raised its fiscal full-year 2020 guidance.
Catalent Makes $315 Million Acquisition in Cellular Medicine
The drug manufacturer is doubling down on biologic drugs to grow profits, but not all of the additional earnings will trickle down the income statement for individual investors.
Here's Why Ziopharm Oncology Fell as Much as 14.0% Today
The small-cap pharmaceutical company announced the pricing of a public stock offering.
Here's Why CRISPR Stocks Fell in January
What's expected to be a busy year for CRISPR stocks started off with a thud, not a bang.
3 Reasons Wind Power Is Poised for a Breakout in 2020
The wind drought that plagued investors in 2018 and 2019 is likely over, but that's only one of the factors to consider.